Research ArticleDrug Discovery and Translational Medicine
Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor–Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury
Andrew J. Haak, Pei-Suen Tsou, Mohammad A. Amin, Jeffrey H. Ruth, Phillip Campbell, David A. Fox, Dinesh Khanna, Scott D. Larsen and Richard R. Neubig
Journal of Pharmacology and Experimental Therapeutics June 2014, 349 (3) 480-486; DOI: https://doi.org/10.1124/jpet.114.213520
Andrew J. Haak
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Pei-Suen Tsou
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Mohammad A. Amin
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Jeffrey H. Ruth
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Phillip Campbell
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
David A. Fox
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Dinesh Khanna
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Scott D. Larsen
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
Richard R. Neubig
Department of Pharmacology (A.J.H.) and Department of Internal Medicine, Division of Rheumatology (P.T., M.A.A., J.H.R., P.C., D.A.F., D.K.), University of Michigan Medical Center, Ann Arbor, Michigan; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (S.D.L.); and Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (R.R.N.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Rho GTPase–Pathway Inhibitor Reduces Markers of Fibrosis
Andrew J. Haak, Pei-Suen Tsou, Mohammad A. Amin, Jeffrey H. Ruth, Phillip Campbell, David A. Fox, Dinesh Khanna, Scott D. Larsen and Richard R. Neubig
Journal of Pharmacology and Experimental Therapeutics June 1, 2014, 349 (3) 480-486; DOI: https://doi.org/10.1124/jpet.114.213520
Research ArticleDrug Discovery and Translational Medicine
Rho GTPase–Pathway Inhibitor Reduces Markers of Fibrosis
Andrew J. Haak, Pei-Suen Tsou, Mohammad A. Amin, Jeffrey H. Ruth, Phillip Campbell, David A. Fox, Dinesh Khanna, Scott D. Larsen and Richard R. Neubig
Journal of Pharmacology and Experimental Therapeutics June 1, 2014, 349 (3) 480-486; DOI: https://doi.org/10.1124/jpet.114.213520
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement